Completed PHASE3 INTERVENTIONAL 1-arm NCT00478114

Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)

An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma

Sponsor: Bayer

Conditions Renal Cell Carcinoma

Interventions sorafenib

Updated 5 times since 2017 Last updated: Aug 25, 2011 Started: May 31, 2007 Primary completion: Aug 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Renal Cell Carcinoma, this trial is completed. The trial is conducted by Bayer and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Mahidol University

Data source: Mahidol University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkoknoi, Thailand